Can GPs legally prescribe CJC1295 or Ipamorelin?

These peptides are not TGA-approved for any indication. A medical practitioner can access unapproved medicines under TGA pathways (Special Access Scheme Category A or B, or Authorised Prescriber), but the TGA has stated these peptides have not been assessed for safety, quality or effectiveness. Clinical professor Alistair Vickery, commissioned by the Medical Board of Australia to review Norton's case, found there is insufficient evidence that CJC1295 and Ipamorelin are safe, effective or beneficial for human use. The coroner's recommendation to the TGA to consider further restrictions may narrow those pathways. In the meantime, prescribing these substances carries significant regulatory and clinical risk.

What symptoms should alert a GP that a patient may be using peptides?

Patients seeking peptides typically present with concerns about fatigue, slow physical recovery, lean muscle loss, joint pain, or anti-ageing goals. They often do not identify as injecting drug users and may not disclose peptide use without direct questioning. Ask directly about supplement injections and any online or telehealth prescribing they may have received. Emergency department visits linked to cardiovascular events, injection-site reactions, or unexplained systemic symptoms in otherwise well adults should prompt consideration of peptide use.

First confirmed Australian peptide death: coroner urges TGA review

On 30 March 2025, actor and martial artist Richard Norton, 75, collapsed at home and suffered a cardiac arrest. He died that day at Melbourne’s Alfred Hospital. A Victorian coroner has now found his death was triggered by injecting unapproved peptides CJC1295 and Ipamorelin — at a higher dose than his prescribing doctor had instructed. His death is believed to be the first confirmed fatality in Australia from unapproved peptide use.

Norton had sought peptide therapy because he wanted help with fatigue, slow physical recovery, shoulder pain and lean muscle loss — goals that any GP would recognise from a standard consultation with a patient in his demographic. He was not seeking drugs in the way the term usually implies. He was seeking the kind of support that wellness culture has positioned peptides as providing, and he had been through a legitimate prescribing pathway: a clinic review, baseline blood tests, a discussion of the treatment’s experimental nature, informed consent, and compounding by a licensed Queensland pharmacy.

The coroner’s findings are not simply about a man who made a poor individual decision.

What the coroner found

Coroner David Ryan delivered his findings on 28 October 2026. He found the cause of death to be cardiac arrest triggered by the peptide injection, and noted that Norton had taken more of the medication than prescribed. The nurse at the clinic had contacted him to say he should administer only the prescribed dose from the following week. Hours later, he became unresponsive after another injection.

Norton’s prescribing doctor, Dr Jerzy Muchnicki, had conducted a careful process by the standards documented in the record: reviewed Norton’s history, discussed the experimental nature of the treatment, arranged baseline blood tests, and had Norton sign an informed consent form. The peptides were compounded by a licensed pharmacy. The Medical Board of Australia’s commissioned expert — clinical professor Alistair Vickery — concluded that Dr Muchnicki’s clinical care was at a reasonably expected standard.

That expert opinion coexists with the Medical Board’s finding that Norton’s clinical notes were inadequate and the practice “is or may be unsatisfactory.” The doctor received a caution and a condition requiring one-on-one education in clinical record keeping. The Board did not pursue further regulatory action.

The coroner’s recommendation is directed at the regulator: the TGA should review the therapeutic benefits and safety risks of CJC1295 and Ipamorelin and consider whether further restrictions should apply.

Regulatory context

The TGA continues to warn consumers that unapproved peptides have not been assessed for safety, quality or effectiveness. The agency has also issued warnings to health practitioners. It is still assessing the risks and considering further regulatory or other measures.

What the coroner’s report puts on record is the mechanism. Various TGA pathways allow medical practitioners to access unapproved medicines, including peptides. The consent and compounding infrastructure exists. Patients can receive these substances through a process that looks, from the outside, like normal medicine. The problem is that “looking like normal medicine” is not the same as being evidence-based.

Professor Vickery’s summary is the key clinical statement here: there is insufficient evidence that CJC1295 and Ipamorelin are safe, effective or beneficial for human use. That is not a minority view among cautious experts. It is the conclusion reached by the expert the Medical Board itself commissioned to review the case.

Both-and: individual care versus systemic risk

The both-and here is genuine. Dr Muchnicki conducted a process that included the elements most GPs would expect in a legitimate prescribing decision: history, discussion of uncertainty, baseline investigation, consent. The outcome was still a death, and the expert found the evidence base does not support the treatment.

That gap — between a process that looks careful and a substance that has no reliable evidence of benefit — is the systemic problem. The coroner’s recommendation is not about one doctor’s record-keeping. It is about whether the regulatory pathways that currently allow access to CJC1295 and Ipamorelin are calibrated to the actual evidence base, which is thin, and the actual risk, which has now produced a confirmed death.

In the same month as the coroner’s findings, NSW emergency departments reported a surge in presentations linked to peptide use, and the TGA has separately warned about peptide use in patients preparing for surgery. The pattern across these three stories is consistent: a class of substances with no approved indications, a growing patient demand driven by wellness culture, and a healthcare system that has not yet calibrated a clear response.

2 cents: the GP consultation that matters

For GPs: patients are arriving in consultations seeking peptides, often without disclosing it. They do not think of themselves as injecting drug users. They think of themselves as optimising their health, and wellness marketing has built an infrastructure — telehealth clinics, compounding pharmacies, online communities — around that framing.

Direct questioning helps. Ask about supplement injections, online or telehealth prescribing, anything bought from compounding pharmacies. The answer may be buried under a presenting concern about fatigue or physical performance.

The evidence position is clear: CJC1295 and Ipamorelin have not been assessed for safety, quality or effectiveness, and the expert evidence before the Medical Board found insufficient basis to conclude they are safe or beneficial. That is the clinical statement you can offer a patient who asks. The coroner’s findings are now the regulatory-accountability layer on top of it.

Verdict: yes — the first confirmed Australian fatality from unapproved peptide use, with a coroner’s recommendation to the TGA, is a clinical-safety story every GP prescribing or fielding questions about peptides needs to read.